Sandoz Group AG Sponsored ADR (SDZNY)
(Delayed Data from OTC)
$35.59 USD
+0.46 (1.31%)
Updated Jun 6, 2024 03:52 PM ET
4-Sell of 5 4
B Value C Growth D Momentum B VGM
Price, Consensus and EPS Surprise
SDZNY 35.59 +0.46(1.31%)
Will SDZNY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SDZNY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SDZNY
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs
AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View
SDZNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SDZNY
Improving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolio
Sandoz Canada announces launch of lisdexamfetamine
Sandoz receives EC approval for Wyost, Jubbonti in Europe
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Sandoz price target raised by CHF 3 at Berenberg